ClinicalTrials.gg
TerminatedNCT04604184Updated Apr 11, 2022Results posted

ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19

A Phase 2 interventional study of BI 764198 and Placebo in COVID-19, sponsored by Boehringer Ingelheim. Terminated at 25 sites in 6 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-04-11.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Why this study was terminated
Company decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
560th of 1,321
133 · median 91
Started
2020
with 817 others
Phase 2
349 of 1,859
14 open now
Registered
767th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 560th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 767th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults with COVID-19 infection who are in hospital and receive oxygen. Participants need to be 50 years of age or older and need to be at risk of further worsening of their condition.

The purpose of the study is to find out whether a medicine called BI 764198 helps people with COVID-19 infection and breathing problems. BI 764198 may prevent cell death and swelling of the lung tissue and therefore help patients with COVID-19 infection.

Participants are put into 2 groups by chance. One group of participants gets BI 764198 capsules and the other group gets placebo capsules. The placebo capsules look exactly like the BI 764198 capsules but do not contain any medicine. Participants take 1 capsule per day.

Participants are in the study for about a month. At study end, doctors compare the 2 groups for the number of patients that are alive and do not need mechanical breathing support. During the study, the doctors collect information on any health problems of the participants.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 50 years
  • SARS-CoV-2 infection positive confirmed by PCR or approved point-of-care test
  • A score of 5 (hospitalised; oxygen by mask or nasal prongs) or 6 (hospitalised; oxygen by non-invasive ventilation or high flow), but not previously ≥7, on the WHO Clinical Progression Scale.
  • Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial.
  • Male or female patients. Women of (WOCBP) and men able to father a child must abstain from male female sex or must use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly during hospitalisation for at least 7 days after last trial drug intake

Exclusion criteria

Exclusion Criteria:

  • (ALT)/aspartate aminotransferase (AST) >5 × the (ULN).
  • Known active infection with or or C.
  • Pulmonary oedema/respiratory failure due to cardiogenic insult.
  • Previous to hospitalisation, on long-term oxygen therapy.
  • A confirmed baseline prolongation of to greater than 450 ms in males or 470 ms in females according to the Bazett formula, or any other relevant finding at screening, or concomitant use of medication prolonging QT interval.
  • Stage 4 severe chronic kidney disease or requiring dialysis (i.e., \<30 mL/min/1.73 m2).

History of the following cardiac conditions:

  • Myocardial infarction within 3 months prior to the first dose
  • Unstable angina
  • History of long QT features on electrocardiogram (ECG) or history of familial long QT

    • Anticipated transfer/discharge to another hospital or care facility other than their place of residence
    • Further exclusion criteria apply
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    BI 764198 treatment group

    Drug: BI 764198

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Alive and Free of Mechanical Ventilation

    Percentage of patients alive and free of mechanical ventilation at Day 29 is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).

    Time frame: At Day 29

Secondary outcomes

  1. Percentage of Patients Alive and Discharged Free of Oxygen Use

    Percentage of patients alive and discharged free of oxygen use is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).

    Time frame: At Day 29

  2. Percentage of Patients With Occurrence of Any Component of Composite: In-hospital Mortality or Intensive Care Unit (ICU) Admission or Mechanical Ventilation

    Percentage of patients with occurrence of any component of composite: In-hospital mortality or intensive care unit (ICU) admission or mechanical ventilation is presented. Efficacy endpoint meets when a patient has occurrence of any component of composite: In-hospital mortality or intensive care unit (ICU) admission or mechanical ventilation at Day 29. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).

    Time frame: At Day 29

  3. Time to Clinical Improvement of at Least 2 Points (From Randomisation) on the World Health Organization Clinical Progression Scale, Discharge From the Hospital, or Considered Fit for Discharge

    Meets when improvement of at least 2 points on World Health Organization (WHO) Clinical Progression Scale (CPS), discharge from hospital, fit for discharge (score 0, 1, 2, 3 on CPS), whichever comes first. WHO CPS: 0. Uninfected; no viral RNA detected; 1. Asymptomatic; viral RNA detected; 2. Symptomatic; independent; 3. Symptomatic; assistance needed; 4. Hospitalised; no oxygen therapy; 5. Hospitalised; oxygen by mask or nasal prongs; 6. Hospitalised; oxygen by non-invasive ventilation or high flow; 7. Intubation + mechanical ventilation, partial pressure of oxygen/fraction of inspired oxygen (pO2/FiO2) ≥150 or oxygen saturation/FiO2 (SpO2/FiO2) ≥200; 8. Mechanical ventilation pO2/FiO2 \<150 (SpO2/FiO2 \<200) or vasopressors; 9. Mechanical ventilation pO2/FiO2 \<150 + vasopressors, dialysis, extracorporeal membrane oxygenation (ECMO); 10. Death Only patients with event were analysed. One patient had no creatinine at baseline value, therefore excluded from statistical analysis (N=128).

    Time frame: Up to Day 29

  4. Number of Ventilator Free Days

    Number of ventilator free days by Day 29 is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).

    Time frame: Up to Day 29

  5. Percentage of Mortality at Day 15, 29, 60 and 90

    Percentage of mortality is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).

    Time frame: At Day 15, 29, 60 and 90

07

Results

Posted Apr 11, 2022
Limitations and caveats
This trial was terminated early following the recommendation of a Data Monitoring Committee.

Participant flow

This randomised, placebo-controlled, double-blind, proof-of-concept exploratory trial was to evaluate the efficacy and safety of BI 764198, an inhibitor of the transient receptor potential subtype C6 (TRPC6), compared to placebo in reducing risk or severity of acute respiratory distress syndrome (ARDS) in patients hospitalised for coronavirus disease appeared in 2019 (COVID-19).

Participant flow — Overall Study
MilestoneBI 764198 Treatment GroupPlacebo
Started6766
Treated6564
Completed4747
Not completed2019
Withdrew: Adverse event55
Withdrew: Death21
Withdrew: Withdrawal by subject13
Withdrew: Not treated22
Withdrew: Due to sponsor decision97
Withdrew: Physician decision01
Withdrew: Transfer to healthcare10

Outcome measures

PrimaryPercentage of Patients Alive and Free of Mechanical Ventilation

Percentage of patients alive and free of mechanical ventilation at Day 29 is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).

Time frame:
At Day 29
Reported as:
Number · Percentage of patients
Percentage of Patients Alive and Free of Mechanical Ventilation
Percentage of patientsBI 764198 Treatment GroupPlacebo
Percentage of Patients Alive and Free of Mechanical Ventilation83.187.5
Statistical analysis
  • BI 764198 Treatment Group vs Placebo · Regression, Logistic · p = 0.3232 · Risk difference (rd): -5.39 · 95% CI -16.08 to 5.30includes treatment, age, severity grade and creatinine at baseline, duration of symptoms before hospitalisation as covariates
SecondaryPercentage of Patients Alive and Discharged Free of Oxygen Use

Percentage of patients alive and discharged free of oxygen use is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).

Time frame:
At Day 29
Reported as:
Number · Percentage of patients
Percentage of Patients Alive and Discharged Free of Oxygen Use
Percentage of patientsBI 764198 Treatment GroupPlacebo
Percentage of Patients Alive and Discharged Free of Oxygen Use75.482.8
Statistical analysis
  • BI 764198 Treatment Group vs Placebo · Regression, Logistic · p = 0.1274 · Risk difference (rd): -9.86 · 95% CI -22.54 to 2.82includes treatment, age, severity grade and creatinine at baseline, duration of symptoms before hospitalisation as covariates
SecondaryPercentage of Patients With Occurrence of Any Component of Composite: In-hospital Mortality or Intensive Care Unit (ICU) Admission or Mechanical Ventilation

Percentage of patients with occurrence of any component of composite: In-hospital mortality or intensive care unit (ICU) admission or mechanical ventilation is presented. Efficacy endpoint meets when a patient has occurrence of any component of composite: In-hospital mortality or intensive care unit (ICU) admission or mechanical ventilation at Day 29. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).

Time frame:
At Day 29
Reported as:
Number · Percentage of patients
Percentage of Patients With Occurrence of Any Component of Composite: In-hospital Mortality or Intensive Care Unit (ICU) Admission or Mechanical Ventilation
Percentage of patientsBI 764198 Treatment GroupPlacebo
Percentage of Patients With Occurrence of Any Component of Composite: In-hospital Mortality or Intensive Care Unit (ICU) Admission or Mechanical Ventilation26.223.4
Statistical analysis
  • BI 764198 Treatment Group vs Placebo · Regression, Logistic · p = 0.6828 · Risk difference (rd): 2.66 · 95% CI -10.11 to 15.43includes treatment, age, severity grade and creatinine at baseline, duration of symptoms before hospitalisation as covariates
SecondaryTime to Clinical Improvement of at Least 2 Points (From Randomisation) on the World Health Organization Clinical Progression Scale, Discharge From the Hospital, or Considered Fit for Discharge

Meets when improvement of at least 2 points on World Health Organization (WHO) Clinical Progression Scale (CPS), discharge from hospital, fit for discharge (score 0, 1, 2, 3 on CPS), whichever comes first. WHO CPS: 0. Uninfected; no viral RNA detected; 1. Asymptomatic; viral RNA detected; 2. Symptomatic; independent; 3. Symptomatic; assistance needed; 4. Hospitalised; no oxygen therapy; 5. Hospitalised; oxygen by mask or nasal prongs; 6. Hospitalised; oxygen by non-invasive ventilation or high flow; 7. Intubation + mechanical ventilation, partial pressure of oxygen/fraction of inspired oxygen (pO2/FiO2) ≥150 or oxygen saturation/FiO2 (SpO2/FiO2) ≥200; 8. Mechanical ventilation pO2/FiO2 \<150 (SpO2/FiO2 \<200) or vasopressors; 9. Mechanical ventilation pO2/FiO2 \<150 + vasopressors, dialysis, extracorporeal membrane oxygenation (ECMO); 10. Death Only patients with event were analysed. One patient had no creatinine at baseline value, therefore excluded from statistical analysis (N=128).

Time frame:
Up to Day 29
Reported as:
Median · Days
Time to Clinical Improvement of at Least 2 Points (From Randomisation) on the World Health Organization Clinical Progression Scale, Discharge From the Hospital, or Considered Fit for Discharge
DaysBI 764198 Treatment GroupPlacebo
Time to Clinical Improvement of at Least 2 Points (From Randomisation) on the World Health Organization Clinical Progression Scale, Discharge From the Hospital, or Considered Fit for Discharge9 (6 to 24)7 (5 to 10)
Statistical analysis
  • BI 764198 Treatment Group vs Placebo · Regression, Cox · p = 0.0445 · Rate ratio: 0.67 · 95% CI 0.46 to 0.99Covariates are treatment, age, severity grade and creatinine at baseline and duration of symptoms before hospitalization
SecondaryNumber of Ventilator Free Days

Number of ventilator free days by Day 29 is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).

Time frame:
Up to Day 29
Reported as:
Mean · Days
Number of Ventilator Free Days
DaysBI 764198 Treatment GroupPlacebo
Number of Ventilator Free Days24.12 ± 8.8125.08 ± 7.85
Statistical analysis
  • BI 764198 Treatment Group vs Placebo · ANCOVA · p = 0.5526 · Mean difference (net): -0.80 · 95% CI -3.47 to 1.87Difference = covariate adjusted BI 764198 - covariate adjusted Placebo
SecondaryPercentage of Mortality at Day 15, 29, 60 and 90

Percentage of mortality is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).

Time frame:
At Day 15, 29, 60 and 90
Reported as:
Number · Percentage of patients
Percentage of Mortality at Day 15, 29, 60 and 90
Percentage of patientsBI 764198 Treatment GroupPlacebo
Day 156.21.6
Day 2912.37.8
Day 6015.47.8
Day 9016.97.8
Statistical analysis
  • BI 764198 Treatment Group vs Placebo · Regression, Logistic · p = 0.0995 · Risk difference (rd): 5.32 · 95% CI -1.01 to 11.65Includes treatment, age, severity grade and creatinine at baseline, and duration of symptoms before hospitalisation as covariates
  • BI 764198 Treatment Group vs Placebo · Regression, Logistic · p = 0.1992 · Risk difference (rd): 6.06 · 95% CI -3.19 to 15.31Includes treatment, age, severity grade and creatinine at baseline, and duration of symptoms before hospitalisation as covariates
  • BI 764198 Treatment Group vs Placebo · Regression, Logistic · p = 0.0709 · Risk difference (rd): 8.93 · 95% CI -0.76 to 18.62Includes treatment, age, severity grade and creatinine at baseline, and duration of symptoms before hospitalisation as covariates
  • BI 764198 Treatment Group vs Placebo · Regression, Logistic · p = 0.0412 · Risk difference (rd): 10.35 · 95% CI 0.41 to 20.28Includes treatment, age, severity grade and creatinine at baseline, and duration of symptoms before hospitalisation as covariates

Adverse events

Collected over From first administration of the study drug to end of study, 90 days in total.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BI 764198 Treatment Group11/65 (16.9%)19/65 (29.2%)10/65 (15.4%)
Placebo5/64 (7.8%)17/64 (26.6%)12/64 (18.8%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventBI 764198 Treatment GroupPlacebo
Acute kidney injuryRenal and urinary disorders4/655/64
Respiratory failureRespiratory, thoracic and mediastinal disorders4/655/64
COVID-19 pneumoniaInfections and infestations4/652/64
Septic shockInfections and infestations2/653/64
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders2/653/64
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/652/64
Cardiac failure congestiveCardiac disorders0/652/64
COVID-19Infections and infestations1/652/64
PneumothoraxRespiratory, thoracic and mediastinal disorders1/652/64
HypoxiaRespiratory, thoracic and mediastinal disorders2/650/64
Most frequent other events
Most frequent other events
EventBI 764198 Treatment GroupPlacebo
ConstipationGastrointestinal disorders4/656/64
HyperkalaemiaMetabolism and nutrition disorders2/656/64
HypotensionVascular disorders4/655/64
Electrocardiogram QT prolongedInvestigations3/654/64
TachycardiaCardiac disorders0/654/64

Baseline characteristics

Full Analysis Set (FAS): FAS included all patients (pts) in randomized set (RS) who received at least 1 dose of trial drug, comprised 129 pts (85.4%). Of all pts randomised, number (%) of pts not treated was similar in BI 764198 (2/67 pts \[3.0%\]) and placebo group (2/66 pts \[3.0%\]). The 4 pts excluded from FAS discontinued trial before receiving treatment for following reasons: pt's withdrawal (n=2), meeting an exclusion criterion (n=1), and clinical worsening (n=1).

Age, Continuous
Age, Continuous(Years)BI 764198 Treatment GroupPlaceboTotal
Mean63.8 ± 8.363.6 ± 7.963.7 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)BI 764198 Treatment GroupPlaceboTotal
Female242549
Male413980
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BI 764198 Treatment GroupPlaceboTotal
Hispanic or Latino393574
Not Hispanic or Latino262955
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BI 764198 Treatment GroupPlaceboTotal
American Indian or Alaska Native5712
Asian033
Native Hawaiian or Other Pacific Islander202
Black or African American336
White5347100
More than one race000
Unknown or Not Reported246
08

Study locations

25 sites
  • University of California Irvine
    Orange, California 92868, United States
  • Rapides Regional Medical Center
    Alexandria, Louisiana 71301, United States
  • St. Elizabeth's Medical Center
    Boston, Massachusetts 02135, United States
  • Newton-Wellesley Hospital
    Newton, Massachusetts 02462, United States
  • Mercy Health St. Vincent Medical Center
    Toledo, Ohio 43608, United States
  • Providence Regional Medical Center
    Everett, Washington 98201, United States
  • MultiCare Tacoma General Hospital
    Tacoma, Washington 98405, United States
  • Hospital Luxemburgo
    Belo Horizonte, 32380-490, Brazil
  • IPECC - Instituto de Pesquisa Clínica de Campinas
    Campinas, 13060-080, Brazil
  • Hospital Ernesto Dornelles
    Porto Alegre, 90160-092, Brazil
  • Hospital Regional Hans Dieter Schmidt
    Santa Catarina, 89227, Brazil
  • Hospital de Base - Fac Med de Sao Jose do Rio Preto
    Sao Jose do Rio Preto, 15090-000, Brazil
  • Hospital Padre Alberto Hurtado
    Santiago, 8880465, Chile
  • Hospital Carlos Van Buren
    Valparaiso, 2341131, Chile
  • Hospital Cardiologica Aguascalientes
    Aguascalientes, 20230, Mexico
  • Hospital General de Culiacán "Dr. Bernardo J. Gastellum"
    Culiacán, 80230, Mexico
  • Hospital Universitario Dr Jose Eleuterio Gonzalez
    Monterrey, 64460, Mexico
  • Hospital Auxilio Mutuo
    Hato Rey, 00919, Puerto Rico
  • Hospital Municipal de San Juan
    Rio Piedras, 00936, Puerto Rico
  • Hospital A Coruña
    A Coruña, 15006, Spain
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, 28031, Spain
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Son Espases
    Palma de Mallorca, 07120, Spain
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Mar 2021, 4 months.

Results were first posted in Apr 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2020
First posted
Oct 27, 2020
StartActual
Nov 3, 2020
Primary completionActual
Mar 24, 2021
CompletionActual
May 31, 2021
Results first posted
Apr 11, 2022
Last update
Apr 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04604184
Responsible party
Sponsor
First posted
Oct 27, 2020
Start date
Nov 3, 2020
Primary completion
Mar 24, 2021
Completion
May 31, 2021
Results posted
Apr 11, 2022
Last update
Apr 11, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI-764198

Start the discussion